Conclusion: Overall, GJB3 shows potential as a molecular biomarker and therapeutic target for various cancers, particularly lung adenocarcinomas, mesothelioma, pancreatic adenocarcinoma. This evidence concerns the gene GJB3 and pancreatic adenocarcinoma.